Bill > S4785

This bill, the Responsibility in Drug Advertising Act of 2024, aims to amend the Federal Food, Drug, and Cosmetic Act to restrict direct-to-consumer drug advertising. The key provisions of the bill include: (1) a prohibition on direct-to-consumer advertising, including on social media platforms, for the first 3 years after a drug's approval, with a possible waiver during the third year if the Secretary of Health and Human Services determines that the advertising would have an affirmative value to public health; and (2) the ability for the Secretary to prohibit direct-to-consumer advertising of a drug after the initial 3-year period if they determine the drug has significant adverse health effects. The bill also requires the Secretary to revise the relevant regulations within 1 year of enactment.